FIBROGEN INC (30) | Intellectual Property (5)

Browse by Subcategory

License Agreements (5)

Recent Contracts

Amended and Restated Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of January 21, 2022 (Filed With SEC on May 9, 2022)
Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of July 16, 2021 (Filed With SEC on November 9, 2021)
Exclusive License and Option Agreement by and between FibroGen, Inc. and HiFiBiO (HK) Limited (D.B.A. HiFiBiO Therapeutics), as of June 16, 2021 (Filed With SEC on August 9, 2021)
Second Amended and Restated License, Development and Commercialization Agreement by and among FibroGen China Anemia Holdings, Ltd., FibroGen China Medical Technology Development... (Filed With SEC on August 6, 2020)
Amendment No. 1 to the Amended and Restated License, Development and Commercialization Agreement by and between FibroGen, Inc. and AstraZeneca AB, effective as of July 1, 2020 (Filed With SEC on August 6, 2020)